Hepatitis Monthly

Published by: Kowsar

Annual Change in FIB-4, but not in APRI, was a Strong Predictor for Liver Disease Progression in Chinese Patients with Chronic Hepatitis C

Li Xiao 1 , 2 , Weihong Wang 3 , Jianchun Xian 2 , Wei Zhang 2 , Yang Li 2 , Xiuzhen Yang 2 and Lungen Lu 1 , *
Authors Information
1 Gastroenterology Department, Shanghai General Hospital of Nanjing Medical University, Shanghai, China
2 Hepatology Department, Taizhou People’s Hospital, Jiangsu, China
3 Hepatology Department, Liaocheng People’s Hospital, Shandong, China
Article information
  • Hepatitis Monthly: March 2018, 18 (3); e57250
  • Published Online: November 16, 2017
  • Article Type: Research Article
  • Received: July 2, 2017
  • Revised: September 13, 2017
  • Accepted: October 14, 2017
  • DOI: 10.5812/hepatmon.57250

To Cite: Xiao L, Wang W, Xian J, Zhang W, Li Y, et al. Annual Change in FIB-4, but not in APRI, was a Strong Predictor for Liver Disease Progression in Chinese Patients with Chronic Hepatitis C, Hepat Mon. 2018 ;18(3):e57250. doi: 10.5812/hepatmon.57250.

Abstract
Copyright © 2017, Hepatitis Monthly. This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.
1. Background
2. Objectives
3. Methods
4. Results
5. Discussion
Footnotes
References
  • 1. Guidelines for the screening, care and treatment of persons with hepatitis C infection. World Health Organization; 2014.World Health Organization.
  • 2. Martinez-Macias RF, Cordero-Perez P, Juarez-Rodriguez OA, Chen-Lopez CY, Martinez-Carrillo FM, Alarcon-Galvan G, et al. Interferon-based therapy delays but metabolic comorbidity accelerates progression of chronic hepatitis C. Ann Hepatol. 2015;14(1):36-45. [PubMed: 25536640].
  • 3. Zeng QL, Feng GH, Zhang JY, Chen Y, Yang B, Huang HH, et al. Risk factors for liver-related mortality in chronic hepatitis C patients: a deceased case-living control study. World J Gastroenterol. 2014;20(18):5519-26. doi: 10.3748/wjg.v20.i18.5519. [PubMed: 24833882].
  • 4. Huang YW, Yang SS, Fu SC, Wang TC, Hsu CK, Chen DS, et al. Increased risk of cirrhosis and its decompensation in chronic hepatitis C patients with new-onset diabetes: a nationwide cohort study. Hepatology. 2014;60(3):807-14. doi: 10.1002/hep.27212. [PubMed: 24919583].
  • 5. Asia-Pacific Working Party on Prevention of Hepatocellular C. Prevention of hepatocellular carcinoma in the Asia-Pacific region: consensus statements. J Gastroenterol Hepatol. 2010;25(4):657-63. doi: 10.1111/j.1440-1746.2009.06167.x. [PubMed: 20492323].
  • 6. Nagao Y, Sata M. Serum albumin and mortality risk in a hyperendemic area of HCV infection in Japan. Virol J. 2010;7:375. doi: 10.1186/1743-422X-7-375. [PubMed: 21194423].
  • 7. Rein DB, Wittenborn JS, Weinbaum CM, Sabin M, Smith BD, Lesesne SB. Forecasting the morbidity and mortality associated with prevalent cases of pre-cirrhotic chronic hepatitis C in the United States. Dig Liver Dis. 2011;43(1):66-72. doi: 10.1016/j.dld.2010.05.006. [PubMed: 20739252].
  • 8. Hu KQ, Tong MJ. The long-term outcomes of patients with compensated hepatitis C virus-related cirrhosis and history of parenteral exposure in the United States. Hepatology. 1999;29(4):1311-6. doi: 10.1002/hep.510290424. [PubMed: 10094980].
  • 9. Rousselet MC, Michalak S, Dupre F, Croue A, Bedossa P, Saint-Andre JP, et al. Sources of variability in histological scoring of chronic viral hepatitis. Hepatology. 2005;41(2):257-64. doi: 10.1002/hep.20535. [PubMed: 15660389].
  • 10. Bedossa P, Dargere D, Paradis V. Sampling variability of liver fibrosis in chronic hepatitis C. Hepatology. 2003;38(6):1449-57. doi: 10.1016/j.hep.2003.09.022. [PubMed: 14647056].
  • 11. Regev A, Berho M, Jeffers LJ, Milikowski C, Molina EG, Pyrsopoulos NT, et al. Sampling error and intraobserver variation in liver biopsy in patients with chronic HCV infection. Am J Gastroenterol. 2002;97(10):2614-8. doi: 10.1111/j.1572-0241.2002.06038.x. [PubMed: 12385448].
  • 12. Kamath PS, Kim WR, Advanced Liver Disease Study G. The model for end-stage liver disease (MELD). Hepatology. 2007;45(3):797-805. doi: 10.1002/hep.21563. [PubMed: 17326206].
  • 13. Pugh RN, Murray-Lyon IM, Dawson JL, Pietroni MC, Williams R. Transection of the oesophagus for bleeding oesophageal varices. Br J Surg. 1973;60(8):646-9. [PubMed: 4541913].
  • 14. Friedrich-Rust M, Ong MF, Martens S, Sarrazin C, Bojunga J, Zeuzem S, et al. Performance of transient elastography for the staging of liver fibrosis: a meta-analysis. Gastroenterology. 2008;134(4):960-74. doi: 10.1053/j.gastro.2008.01.034. [PubMed: 18395077].
  • 15. Ngo Y, Munteanu M, Messous D, Charlotte F, Imbert-Bismut F, Thabut D, et al. A prospective analysis of the prognostic value of biomarkers (FibroTest) in patients with chronic hepatitis C. Clin Chem. 2006;52(10):1887-96. doi: 10.1373/clinchem.2006.070961. [PubMed: 16931569].
  • 16. Wai CT, Greenson JK, Fontana RJ, Kalbfleisch JD, Marrero JA, Conjeevaram HS, et al. A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C. Hepatology. 2003;38(2):518-26. doi: 10.1053/jhep.2003.50346. [PubMed: 12883497].
  • 17. Vallet-Pichard A, Mallet V, Nalpas B, Verkarre V, Nalpas A, Dhalluin-Venier V, et al. FIB-4: an inexpensive and accurate marker of fibrosis in HCV infection. comparison with liver biopsy and fibrotest. Hepatology. 2007;46(1):32-6. doi: 10.1002/hep.21669. [PubMed: 17567829].
  • 18. Tada T, Kumada T, Toyoda H, Kiriyama S, Tanikawa M, Hisanaga Y, et al. Long-term prognosis of patients with chronic hepatitis C who did not receive interferon-based therapy: causes of death and analysis based on the FIB-4 index. J Gastroenterol. 2016;51(4):380-9. doi: 10.1007/s00535-015-1117-5. [PubMed: 26342600].
  • 19. Nunes D, Fleming C, Offner G, Craven D, Fix O, Heeren T, et al. Noninvasive markers of liver fibrosis are highly predictive of liver-related death in a cohort of HCV-infected individuals with and without HIV infection. Am J Gastroenterol. 2010;105(6):1346-53. doi: 10.1038/ajg.2009.746. [PubMed: 20179698].
  • 20. Vergniol J, Boursier J, Coutzac C, Bertrais S, Foucher J, Angel C, et al. Evolution of noninvasive tests of liver fibrosis is associated with prognosis in patients with chronic hepatitis C. Hepatology. 2014;60(1):65-76. doi: 10.1002/hep.27069. [PubMed: 24519328].
  • 21. Vergniol J, Foucher J, Terrebonne E, Bernard PH, le Bail B, Merrouche W, et al. Noninvasive tests for fibrosis and liver stiffness predict 5-year outcomes of patients with chronic hepatitis C. Gastroenterology. 2011;140(7):1970-9. 1979 e1-3. doi: 10.1053/j.gastro.2011.02.058. [PubMed: 21376047].
  • 22. Jain MK, Seremba E, Bhore R, Dao D, Joshi R, Attar N, et al. Change in fibrosis score as a predictor of mortality among HIV-infected patients with viral hepatitis. AIDS Patient Care STDS. 2012;26(2):73-80. doi: 10.1089/apc.2011.0191. [PubMed: 22239101].
  • 23. Bambha K, Pierce C, Cox C, French AL, Tien PC, Sharp GB, et al. Assessing mortality in women with hepatitis C virus and HIV using indirect markers of fibrosis. AIDS. 2012;26(5):599-607. doi: 10.1097/QAD.0b013e32834fa121. [PubMed: 22156972].
  • 24. Rao H, Wei L, Lopez-Talavera JC, Shang J, Chen H, Li J, et al. Distribution and clinical correlates of viral and host genotypes in Chinese patients with chronic hepatitis C virus infection. J Gastroenterol Hepatol. 2014;29(3):545-53. doi: 10.1111/jgh.12398. [PubMed: 24090188].
  • 25. Thomas DL, Thio CL, Martin MP, Qi Y, Ge D, O'Huigin C, et al. Genetic variation in IL28B and spontaneous clearance of hepatitis C virus. Nature. 2009;461(7265):798-801. doi: 10.1038/nature08463. [PubMed: 19759533].
  • 26. Kamper-Jorgensen M, Gronbaek M, Tolstrup J, Becker U. Alcohol and cirrhosis: dose--response or threshold effect? J Hepatol. 2004;41(1):25-30. doi: 10.1016/j.jhep.2004.03.002. [PubMed: 15246203].
  • 27. Asian Pacific Association for the Study of the Liver Hepatitis CP, McCaughan GW, Omata M, Amarapurkar D, Bowden S, Chow WC, et al. Asian Pacific Association for the Study of the Liver consensus statements on the diagnosis, management and treatment of hepatitis C virus infection. J Gastroenterol Hepatol. 2007;22(5):615-33. doi: 10.1111/j.1440-1746.2007.04883.x. [PubMed: 17444847].
  • 28. Bruix J, Sherman M, American Association for the Study of Liver D. Management of hepatocellular carcinoma: an update. Hepatology. 2011;53(3):1020-2. doi: 10.1002/hep.24199. [PubMed: 21374666].
  • 29. Dhiman RK, Agrawal S, Gupta T, Duseja A, Chawla Y. Chronic Liver Failure-Sequential Organ Failure Assessment is better than the Asia-Pacific Association for the Study of Liver criteria for defining acute-on-chronic liver failure and predicting outcome. World J Gastroenterol. 2014;20(40):14934-41. doi: 10.3748/wjg.v20.i40.14934. [PubMed: 25356054].
  • 30. Teshale E, Lu M, Rupp LB, Holmberg SD, Moorman AC, Spradling P, et al. APRI and FIB-4 are good predictors of the stage of liver fibrosis in chronic hepatitis B: the Chronic Hepatitis Cohort Study (CHeCS). J Viral Hepat. 2014;21(12):917-20. doi: 10.1111/jvh.12279. [PubMed: 25131445].
  • 31. Amorim TG, Staub GJ, Lazzarotto C, Silva AP, Manes J, Ferronato Mda G, et al. Validation and comparison of simple noninvasive models for the prediction of liver fibrosis in chronic hepatitis C. Ann Hepatol. 2012;11(6):855-61. [PubMed: 23109448].
  • 32. Berenguer J, Zamora FX, Aldamiz-Echevarria T, Von Wichmann MA, Crespo M, Lopez-Aldeguer J, et al. Comparison of the prognostic value of liver biopsy and FIB-4 index in patients coinfected with HIV and hepatitis C virus. Clin Infect Dis. 2015;60(6):950-8. doi: 10.1093/cid/ciu939. [PubMed: 25422386].
  • 33. Parkes J, Roderick P, Harris S, Day C, Mutimer D, Collier J, et al. Enhanced liver fibrosis test can predict clinical outcomes in patients with chronic liver disease. Gut. 2010;59(9):1245-51. doi: 10.1136/gut.2009.203166. [PubMed: 20675693].
  • 34. Yu ML, Dai CY, Huang JF, Chiu CF, Yang YH, Hou NJ, et al. Rapid virological response and treatment duration for chronic hepatitis C genotype 1 patients: a randomized trial. Hepatology. 2008;47(6):1884-93. doi: 10.1002/hep.22319. [PubMed: 18508296].
  • 35. Lee SD, Yu ML, Cheng PN, Lai MY, Chao YC, Hwang SJ, et al. Comparison of a 6-month course peginterferon alpha-2b plus ribavirin and interferon alpha-2b plus ribavirin in treating Chinese patients with chronic hepatitis C in Taiwan. J Viral Hepat. 2005;12(3):283-91. doi: 10.1111/j.1365-2893.2005.00590.x. [PubMed: 15850469].
  • 36. Petta S, Di Marco V, Bruno S, Enea M, Calvaruso V, Boccaccio V, et al. Impact of virus eradication in patients with compensated hepatitis C virus-related cirrhosis: competing risks and multistate model. Liver Int. 2016;36(12):1765-73. doi: 10.1111/liv.13156. [PubMed: 27164508].
  • 37. Morgan RL, Baack B, Smith BD, Yartel A, Pitasi M, Falck-Ytter Y. Eradication of hepatitis C virus infection and the development of hepatocellular carcinoma: a meta-analysis of observational studies. Ann Intern Med. 2013;158(5 Pt 1):329-37. doi: 10.7326/0003-4819-158-5-201303050-00005. [PubMed: 23460056].
  • 38. van der Meer AJ, Veldt BJ, Feld JJ, Wedemeyer H, Dufour JF, Lammert F, et al. Association between sustained virological response and all-cause mortality among patients with chronic hepatitis C and advanced hepatic fibrosis. JAMA. 2012;308(24):2584-93. doi: 10.1001/jama.2012.144878. [PubMed: 23268517].
  • 39. Cho J, Lee SS, Choi YS, Jeon Y, Chung JW, Baeg JY, et al. Occult hepatitis B virus infection is not associated with disease progression of chronic hepatitis C virus infection. World J Gastroenterol. 2016;22(42):9427-36. doi: 10.3748/wjg.v22.i42.9427. [PubMed: 27895431].
  • 40. Bruno S, Crosignani A, Maisonneuve P, Rossi S, Silini E, Mondelli MU. Hepatitis C virus genotype 1b as a major risk factor associated with hepatocellular carcinoma in patients with cirrhosis: a seventeen-year prospective cohort study. Hepatology. 2007;46(5):1350-6. doi: 10.1002/hep.21826. [PubMed: 17680653].
  • 41. Manns MP, Wedemeyer H, Singer A, Khomutjanskaja N, Dienes HP, Roskams T, et al. Glycyrrhizin in patients who failed previous interferon alpha-based therapies: biochemical and histological effects after 52 weeks. J Viral Hepat. 2012;19(8):537-46. doi: 10.1111/j.1365-2893.2011.01579.x. [PubMed: 22762137].
Creative Commons License Except where otherwise noted, this work is licensed under Creative Commons Attribution Non Commercial 4.0 International License .

Search Relations:

Author(s):

Article(s):

Create Citiation Alert
via Google Reader

Readers' Comments